medicinal products containing chloroquine, hydroxychloroquine – mental disorders
Based on a review of data on the risk of psychiatric disorders with chloroquine or hydroxychloroquine, additional information on the risk of these events was identified. For both substances, psychiatric disorders were found to occur in patients with and without a history of psychiatric disorders. In addition, cases were reported after the use of hydroxychloroquine, indicating that psychiatric disorders may occur soon after the start of treatment. For chloroquine, the data are insufficient to assess the time to onset of adverse manifestations. Therefore, the PRAC committee concluded that the instructions for medical use of medicinal products containing chloroquine and hydroxychloroquine need to be updated with a more complete description of psychiatric disorders and strengthened recommendations for healthcare professionals and patients. The proposed update is the minimum information that should be included, and it should be adapted to any current information in the instructions on suicidal behavior/suicide and psychiatric disorders/reactions.
Registration certificate holders of medicinal products containing chloroquine, hydroxychloroquine must, within 2 months, submit variations to update the instructions for medical use as indicated below (new text is underlined and in bold, text for deletion):
Hydroxychloroquine
In the "Special precautions for use" section of the instructions:
Suicidal behavior and mental disorders
In very rare cases in some patients who received hydroxychloroquine, suicidal behavior and mental disorders have been reported (see section “Adverse reactions”). Psychiatric adverse effects generally occur within the first month after the start of treatment with hydroxychloroquine and have also been reported in patients with no previous history of mental disorders. Patients should be advised to seek medical attention immediately if symptoms of mental disturbance appear during treatment.
Into the "Adverse Reactions" section of the leaflet
Psychiatric disorders
Common: affect lability
Uncommon: nervousness
Frequency not known: suicidal behavior, psychosis, depression, hallucinations, anxiety, agitation, confusion, delusions, mania and sleep disorders.
Перелік лікарських засобів, що містять hydroxychloroquine і дозволені для медичного застосування в Україні (за даними Державного реєстру лікарських засобів станом на 04.01.2021)
Linkhttps://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-23-26-november-2020-prac-meeting_en.pdf